Lannett Reports Insulin Glargine Trial Success

Ready To Present Trial Design For Lantus Rival To FDA

Clinical_Trial
Lannett has announced positive results from a Phase I trial for biosimilar insulin glargine developed with HEC • Source: Shutterstock

More from Biosimilars

More from Products